Bactericidal effects of polyhexamethylene biguanide against intracellular Staphylococcus aureus EMRSA-15 and USA 300

The Journal of Antimicrobial Chemotherapy
Nor Fadhilah KamaruzzamanLiam Good

Abstract

The treatment of skin infections caused by Staphylococcus aureus is limited by acquired antibiotic resistance and poor drug delivery into pathogen and host cells. Here, we investigated the antibacterial activities of six topically used antimicrobials and a cationic polymer, polyhexamethylene biguanide (PHMB), against intracellular MSSA strain RN4420 and MRSA strains EMRSA-15 and USA 300. The MICs of antimicrobials were determined for MSSA and MRSA strains, and the bactericidal activities of nadifloxacin and PHMB against intracellular MRSA were determined using infected keratinocytes. Fluorescein-tagged PHMB (PHMB-FITC) was used to study PHMB uptake, co-localization with intracellular EMRSA-15 and retention in keratinocytes. The mechanism(s) of PHMB uptake into keratinocytes were studied using a dynamin inhibitor, dynasore. Gentamicin, nadifloxacin and PHMB showed the lowest MICs for MRSA. Nadifloxacin at 10 mg/L killed 80% of intracellular EMRSA-15, but was not effective against USA 300. PHMB at 4 mg/L killed almost 100% of intracellular EMRSA-15 and USA 300. PHMB entered keratinocytes, co-localized with intracellular EMRSA-15 and was retained by the cells for over 5 h. PHMB uptake and its intracellular antibacterial activities...Continue Reading

References

Dec 1, 1979·Antimicrobial Agents and Chemotherapy·P Vaudaux, F A Waldvogel
Sep 3, 1999·The Journal of Antimicrobial Chemotherapy·P M Shah
Sep 29, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Natalia NekhotiaevaLiam Good
Mar 12, 2005·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·F Van BambekeP M Tulkens
Sep 16, 2005·Journal of Applied Microbiology·P Gilbert, L E Moore
Apr 17, 2008·Methods in Enzymology·Tom KirchhausenHenry E Pelish
Jan 27, 2009·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J A OtterG L French
Feb 12, 2009·Trends in Microbiology·Christian Garzoni, William L Kelley
Jul 18, 2009·The Journal of Antimicrobial Chemotherapy·Fred C Tenover, Richard V Goering
Aug 14, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jean B PatelJohn A Jernigan
Oct 22, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Benjamin A Lipsky, Christopher Hoey
Sep 21, 2010·Skin Pharmacology and Physiology·K Kaehn
Oct 12, 2010·The Journal of Antimicrobial Chemotherapy·Matthew S Dryden
Jan 7, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Catherine LiuUNKNOWN Infectious Diseases Society of America
Mar 17, 2011·Nature Reviews. Microbiology·Elizabeth A Grice, Julia A Segre
Mar 30, 2011·Journal of Visualized Experiments : JoVE·Andrew M Edwards, Ruth C Massey
Aug 10, 2012·British Journal of Nursing : BJN·Martyn Butcher
Aug 25, 2012·Frontiers in Cellular and Infection Microbiology·Martin Fraunholz, Bhanu Sinha
Mar 2, 2013·JAMA Ophthalmology·Eric G RomanowskiRegis P Kowalski
Feb 12, 2014·Antimicrobial Agents and Chemotherapy·Antonio Di GraziaMaria Luisa Mangoni
Mar 14, 2014·The New England Journal of Medicine·Adam J Singer, David A Talan
Oct 3, 2015·PLoS Neglected Tropical Diseases·Rebuma FirdessaHeidrun Moll
Nov 5, 2015·Nature·Sophie M LeharSanjeev Mariathasan

❮ Previous
Next ❯

Citations

Mar 22, 2016·Scientific Reports·Kantaraja ChinderaLiam Good
Aug 9, 2017·Antimicrobial Agents and Chemotherapy·A RenzoniP François
Mar 20, 2020·Journal of Nanobiotechnology·Antonios KeirouzGiuseppino Fortunato
Dec 21, 2017·Skin Pharmacology and Physiology·Axel KramerOjan Assadian
Jun 7, 2019·International Journal of Molecular Sciences·Nor Fadhilah KamaruzzamanMaria de Fatima Pina
May 12, 2020·Frontiers in Microbiology·Yuan LiuZhiqiang Wang
Dec 8, 2016·British Journal of Pharmacology·Nor Fadhilah KamaruzzamanLiam Good
Jan 1, 2021·Biology Methods and Protocols·Oluwawemimo Adebowale, Liam Good
Feb 2, 2021·Journal of Materials Science·Shreya KanthYashoda Malgar Puttaiahgowda
Sep 25, 2017·Advanced Drug Delivery Reviews·Weiwei GaoLiangfang Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.